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INTRODUCTION
Several studies have now clearly indicated the presence of tumor-associated and
tumor-specific antigens in cells of human malignant melanoma. These antigens have
been identified by means of several quite different techniques, including the use
of antibodies detectable against the antigens, either by means of immunofluores-
cence, (1-5) cytotoxicity (4, 6, 7) or by extracting the antigen and obtaining lines
of precipitation in gel or cellulose acetate membrane (8). More recent studies using
techniques in cellular immunology have also demonstrated antigens against which
lymphocytes (7, 9-13) or macrophages (14), of patients have been shown to react.
In most of the series reasonable agreement exists in that the immune response
against the melanoma cells relates to the natural history of the disease but there
is still considerable controversy as to the exact relationships. The likelihood that
the differences can be explained on the basis of the measurement of different anti-
gens by the different systems obviously has to be considered. It is the purpose
of this paper to present evidence for a variety of antigens in human malignant
melanoma and to suggest from preliminary studies that more than one immune
response is, therefore, possible and that this immune response may differ with the
different antigens at different stages of the disease.
THE ANTIGENS OF MELANOMA CELLS
Membrane Antigens
Using immunofluorescence and complement-dependent cytotoxicity a surface-
membrane antigen has been detected in melanoma cells which appears to be highly
patient specific with little or no cross reactivity at high titer (4, 15). Also more
weakly reacting membrane antigens can be detected which cross-react only at a
very low intensity and virtually disappear if the serum is first diluted to one in four.
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FIG. 1. Surface membrane immunofluorescence on a malignant cell viewed by
epi-illumination.
We have recently developed an anti-human fetal serum by immunizing rabbits
against 12-week-old human fetal material. The results have indicated that the anti-
fetal serum reacts with human fetal cells but not with adult human cells. As
measured by membrane immunofluorescence this serum also reacts with a number
of human tumors including malignant melanoma (16). An example can be seen
in Fig. 1.
Cytoplasmic Antigens
These are detected by means of immunofluorescence on cells which have been
snap frozen on glass with a mixture of isopentane and liquid nitrogen (17, 18).
The antigens appear to be group specific because positive sera from a number of
melanoma patients cross-react widely with a number of melanoma cell prepara-
tions. The degree of intensity of the reaction may be similar in both autologous
and allogeneic situations. Recent studies indicate, however, that cross-reacting al-
logeneic sera are of different sorts: certain sera that give positive autologous reac-
tion, do not cross-react with other melanoma sera that have been reactive with
their own cells. This is especially true in the early stage of melanoma. Again, in
some recent preliminary studies which will be reported in more detail elsewhere,
an antigen in the cytoplasm of ocular melanomas shows some degree of cross-re-
activity but again not as wide a degree of cross-reactivity as that seen either within
ocular melanomas as a group or within cutaneous melanomas as a group (19).
McBride and his colleagues have recently described a nucleolar antigen in mela-














FIG. 2. Diagrammatic representation of different antigens in malignant melanoma cells.
FIG. 3. Cytoplasmic immunofluorescence in snap-frozen melanoma cell.
are not able to confirm their results. We have also noted different diffuse nuclear
patterns in reactions of the sera of certain individuals to melanoma preparations
which cannot be explained on the basis of antinuclear factor. This is, however,
a variable reaction for which there is as yet no satisfactory explanation (See Figs.
2, 3, and 4.).
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FIG. 4. Nuclear and nucleolar staining by immunofluorescence.
QUANTITATION OF IMMUNOFLUORESCENCE
Further light may well be thrown on these various antigens, particularly their
quantitation, by the use of an epi-illumination microscope system with a photo-
electric measurement device. This is a modification of that described by Ploem
(21) and essentially consists of a photometer attached to an epi-illumination Nikon
microscope from which a photoelectric cell and a read-out device allows one, over
a narrow wave band, to measure specific fluorescence in terms of the deflection
of a galvanometer. In studying the reactions of the antibodies against both cyto-
plasmic and membrane fluorescence in melanoma and in other tumors we have
found the following: In each test 50 cells were read and the deflection of the gal-
vanometer was recorded; the results, represented in Figs. 5, 6, and 7, show a scatter
of fluorescent intensity. It can clearly be seen that the controls (phosphate-buffered
saline alone or nonmelanoma serum) show a rather narrow scatter in a low-reading
range (Fig. 5), but even in this a brightly fluorescent cell can occasionally be noted
well into the high-reading range. Visual microscopy has identified these cells as
plasma cells or lymphocytes infiltrating the original tumor preparation. This may
explain the "multiple crossreactivity" which has been recorded when the tumor
cells were not distinguishable from other cells carrying immunoglobulin. It might
also explain how immunoglobulin is eluted from tumor cell preparation. The results
of positive and negative sera against autologous and allogeneic melanoma are
shown in Figs. 6 and 7 and are highly significant. Similar results can be obtained
using membrane fluorescence. This method might obviate the necessity for expres-
sing results as fluorescent indices or as titers. It might also facilitate study of the
antigen-antibody interaction within an individual tumor, and separation of the cross-
reacting and common antigens involved. It also gives a good indication of the
664ANTIGENS IN MELANOMA 665
PHOTOMETRIC QUANTITATION OF IMMUNOFLUORESCENCE


























I I I~~~~~~~~~~~~~~~~~~ T I T I I 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31
INDIVIDUAL CELLS OBSERVED
NON SERA CONTROL / MELANOMA CELLS
FIG. 5. Quantitation in cytoplasmic immunofluorescence:
* 0 0 . 0
S 0 0
I
33 35 37 39 41 43 45 47
Control nonmelanoma sera.
PHOTOMETRIC QUANTITATION OF IMMUNOFLUORESCENCE

























a aa... a.aaaI ....I a 1 a
I I
1 3 s 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 4 47
INDIVIDUAL CELLS OBSERVED
NEGATIVE MELANOMA SERA I MELANOMA CELLS
6. Quantitation in cytoplasmic immunofluorescence: Autologous positive melanoma
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PHOTOMETRIC QUANTITATION OF IMMUNOFLUORESCENCE
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FIG. 7. Quantitation in cytoplasmic immunofluorescence: Allogeneic negative melanoma
sera.
heterogeneity of the cell populations under study. These studies on freshly removed
tumor cells will be compared with various cell lines which have been derived from
such tumor cells to see whether particular types of tumor cell have expressed more
of the various antigens than others, since this may well be of fundamental impor-
tance in the understanding of the variations of the immune response at different
stages of the disease.
Finally, our present impression of the relationships between the antigens and
their antibodies at various stages of the disease are summarized in Fig. 8. The
autologous membrane antigen is the one we have seen most in the early stages
of the tumor. Our preliminary observations in melanoma show that the autologous
anticytoplasmic antibody appears next in line and may well result from local de-
struction of tumor and, therefore, availability of this antigen to the host in general.
Finally, antibodies may be present against the allogeneic cytoplasmic antigen at
a later stage of the disease, particularly if antigen has been liberated during tumor
dissemination. Certainly the antibody against this allogeneic antigen may not be
present even when the antibody against the autologous cytoplasmic antigen is
clearly there (22). The relationship between the antigen of the cytoplasm of the
ocular and cutaneous melanoma is still under investigation. The fundamental ques-
tions to be answered from such investigation are (1) what antigen appears at what
stage of the disease? and (2) can an antigen alone be held responsible for the
apparent fall in immune response in the disseminated phase of melanoma? We
have afready indicated (23) that patients can produce what appear to be either
antibody-antigen complexes or even anti-idiotype antibodies which allow the
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FIG. 8. Diagrammatic summary and proposed relationships between antibodies against
various melanoma antigens at different states in the natural history of malignant melanoma.
various antigens and their appropriate antibodies can be measured in individual
patients over a sequential period of time as the disease progresses from nevus to
disseminated melanoma. So far we have been able to separate, in an individual
serum, an antibody against the surface membrane component as against the cyto-
plasmic autologous component (18), and it is hoped by using bioabsorption col-
umn techniques that the various antigens will be obtained in a relatively pure form
and then the measurement of these in the circulation will complement those studies
already outlined. It will then be possible to study the relationship between humoral
and cellular immune reactions against particular antigens. Therefore, before one
can actually manipulate the immune response to the benefit of the patient we need
to know about antigens and the reactions, both humoral and cellular, against them
as well as their interactions with each other.
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